Mohamed Aseafan

• DOB: 12/Dec/1990
• Nationality: Saint Lucian (Saudi Mother)
• Marital Status: Married

• Saudi Fellowship in medical Oncology 2022
• Saudi Board in internal medicine 2019
• Passed the 1st and 2nd Part exam of MRCPI
• Passed the 1st and 2nd Part exam of internal medicine Arab board
• Passed the 1st Part of MRCP UK
• Good Clinical Practice Certification 2021
• Participated in multiple advisory board.
• Basic life Support course
• Advanced Cardiovascular Life Support course
• Best Junior Resident in Internal Medicine at SFHP 2017
• Saudi medical license exam 2015
• Dean's list at UPP year 2009
• Pre-Advance level in English (EF International school of English in Dublin 2008 & Manchester 2009)

• Chaiman of Medical records committee at SFHP 2022-2025
• Chairman of Internal medicine morbidity and mortality committee at SFHP 2023-Current
• Member of Hospital morbidity and mortality committee at SFHP 2025-Current
• Chairman of Tumor board committee at SFHP 2022-Current
• Member of The Research ethics committee at SFHP 2022-Current
• Member of the biologics and biosimilar committee at SFHP 2022-Current
• Member of American Society of Clinical Oncology 2020-Current
• Member of European Society for Medical Oncology 2023-Current
• Member of the Saudi Society of GI Oncology 2022-Current
• Member of Quality improvement projects committee at SFHP 2022-Current
• Member of the Internal Medicine Residency Training Program Committee at SFHP 2019
• Member of the scientific committee in the Internal Medicine Review Course in 2018 & 2019
• Volunteer in the Colon Cancer Awareness Day in SFHP 2019

Published clinical trial:

• Phase II trial of FOLFIRINOX in advance biliary tract cancer: Cureus 2024; Shouki Bazarbashi, Mohamed Aseafan, Mahmoud A. Elshenawy, Ahmed Alzahrani, Ali H Aljubran, Fahad Almugbel, Noura Alzannan, and Tusneem AM Elhassan.
• Prognostic significance of peritoneal metastasis from colorectal cancer treated with first-line triplet chemotherapy: World Journal of Clinical Cases 2022; Shouki Bazarbashi, Abdulrahman Alghabban, Mohamed Aseafan, Ali H Aljubran, Ahmed Alzahrani and Tusneem Elhassan.

Published articles:

• Treatment Outcome and Chemoresistance-Related Factors of Low-Risk Gestational Trophoblastic Neoplasia: Results From a Tertiary Care Center in Saudi Arabia; JCO Global Oncology 2025; Mohamed Aseafan, Bader Alshamsan, Inaam Ahmed Ibrahim, et al.
• Docetaxel versus androgen receptor pathway inhibitors as first-line therapy for metastatic castration-resistant prostate cancer after doublet therapy: a multicenter retrospective study from Saudi Arabia; BMC urology 2025; Shouki Bazarbashi, Ahmed S Abdelmotal, Tarek Arabi, Waleed Fallatah, Noura Alzannan, Tusneem Elhassan, Mohamed Aseafan, et al.
• Nationwide Prevalence of Hepatocellular Carcinoma in Saudi Arabia: A Population-Based Analysis for 2021; Journal of Hepatocellular Carcinoma 2025; Edward B De Vol, Shouki Bazarbashi, Mohamed Aseafan, et al.
• Management of metastatic colorectal cancer: consensus in the Gulf Cooperation Council countries; Therapeutic Advances in Medical Oncology 2025; Bazarbashi Shouki, Alnajjar Abdelsalam, Al Sharm Abdullah, Alshammari Kanan, Al Sherhi Ahmed, Dawoud Emad, Heinemann Volker, Aseafan Mohamed, et al.
• Real-world clinical outcome of unresectable locally advanced & de-novo metastatic pancreatic ductal adenocarcinoma: a multicentre retrospective study; BMC cancer 2025; M Aseafan, AH Alfakeeh, E Tashkandi, et al.
• Prognostic significance of the neutrophil to lymphocyte ratio in locally advanced breast cancer; Oncology Letters 2024; B Alshamsan, MA Elshenawy, M Aseafan, et al.
• Efficacy of Chemotherapy Rechallenge Versus Regorafenib or Trifluridine/Tipiracil in Third Line Setting of Metastatic Colorectal Cancer: A Multicenter Retrospective Comparative Study; JCO Global Oncology 2024; Shouki Bazarbashi, Radwan Alkhatib, Mohamed Aseafan, et al.
• Outcomes of Autologous stem cell transplantation in patients with primary refractory Diffuse Large B-cell lymphoma who demonstrate chemosensitivity to salvage chemotherapy; Clinical Hematology International 2024; Rauf MS, Maghfoor I, Aseafan M, et al.
• Characteristics and Treatment Results of Patients with Gastroenteropancreatic Neuroendocrine Tumors in a Tertiary Care Centre: BMC Endocrine Disorders 2023; Shouki Bazarbashi, Mohamed Aseafan, Tasnim Elgazzar, Maha Alkhayat, Abdulrahman Alghabban, Marwa I. Abdelgawad, Bader Alshamsan, Aisha Alshibany, Tusneem Elhassan, Ali Aljubran, Ahmed Alzahrani, Hindi Alhindi, and Hussein Raef.
• Characteristics and outcomes of small bowel adenocarcinoma: 14 years of experience at a single tertiary hospital in Saudi Arabia: MOLECULAR AND CLINICAL ONCOLOGY 2023; Bader Alshamsan, Mohamed Aseafan, Ahmed Badran, Amgad Shaheen, Mahmoud A. Elshenawy, Shouki Bazarbashi, and Ali H. Aljubran.
• Population-based Survival for Cancer Patients in Saudi Arabia for The Years 2005-2009: Scientific Reports 2022; Mohamed Aseafan MBBS1, Edward Devol PhD2, Mahmoud AlAhwal MD3, Riad Souissi MSc4, Reham Sindi BSc5, Haya AlEid MSc6, and Shouki Bazarbashi MBBS7
• Prognostic significance of peritoneal metastasis from colorectal cancer treated with first-line triplet chemotherapy: World Journal of Clinical Cases 2022; Shouki Bazarbashi, Abdulrahman Alghabban, Mohamed Aseafan, Ali H Aljubran, Ahmed Alzahrani and Tusneem AM Elhassan.
• Outcomes and Prognostic Factors of Metastatic Gastric Cancer: A Single-Center Experience: Cureus 2022; Mohamed Aseafan, Ahmed Mostafa Gad, Bader Alshamsan, Naela Agha, Ali Alhanash, Ali H. Aljubran, Ahmed Alzahrani, Shouki Bazarbashi
• Outcomes of Patients with Metastatic Colorectal Cancer Treated with Trifluridine/Tipiracil beyond the Second Line: A Multicenter Retrospective Study from Saudi Arabia: Journal of Oncology 2022; Mohammed Alghamdi, Shouki Bazarbashi, Mervat Mahrous, Omar Alshaer, Ahmed Mostafa Gad, Mohamed Aseafan, Mai Abdelgelil, Redhwan Mohammed Alshabi, Hosam Ali Alghanmi, Nasser Ahmed Naser, Husam Al Hariri, Abdulaziz ALHamad, Khalid Al-Saleh, Nashwa Abdel-Aziz , and Sherif Elsamany
• Thromboembolic Events Burden in Patients With Solid Tumors and Their Predisposing Factors: Cureus 2022; Shouki Bazarbashi, Turkiah Alkhaldi, Mohamed Aseafan, Maryam Melaibari, Sara Almuhisen, Samar Alharbi, Abdulrahman Alghabban, Jihad Aljumaa, Abdelmoneim Eldali, Fatma Maraiki, Tarek Owaidah, Hazzaa Alzahrani.
• Pazopanib as Treatment Option for Pseudomyogenic Hemangioendothelioma: A Case Report: Cureus 2022; Ali Alhanash, Mohamed Aseafan, Jean Atallah.
• Adjuvant abemaciclib‑induced pneumonitis: A case report and review of the literature: World Academy of Science Journal 2021; ABDULRAHMAN AL‑GHABBAN, AISHA AL‑SHIBANY, KHADIJA AL‑SHANGITI, MOHAMED ASEAFAN, KOUSAY LATIF and TAHER AL‑TWEIGERI.
• Thyroid Abscess in a Young Postpartum Female: Cureus 2022; Almdallaleh S, Aseafan M, Khan L.

Published Abstracts & Posters:

• Efficacy and safety of second-line lenvatinib after progression on immunotherapy in advanced hepatocellular carcinoma: A systematic review and meta-analysis. Journal of Clinical Oncology 2025; Tarek Arabi, Abdullah Alruwaili, Mohamed Aseafan, et al.
• Real-world outcomes of nivolumab plus ipilimumab versus immune checkpoint inhibitor and tyrosine kinase inhibitor combinations as first-line treatment for metastatic clear cell; Journal of Clinical Oncology 2025; Faisal Azam, Mubarak Mahdi Almansour, Bassam Mohammed Basulaiman, Mohamed Aseafan, et al.
• Real-World Clinical Outcomes of Locally Advanced Unresectable and De-novo Metastatic Pancreatic Ductal Adenocarcinoma: A Multicentre Retrospective Study from Saudi Arabia; ASCO GI 2025; Mohamed Aseafan, et al.
• Enhancing management of localized gastric cancer: The added value of prophylactic HIPEC and IORT to conventional surgery; Annals of Oncology 2024; Bazarbashi, H Elwaheidi, A Sheikh, A Aljuhani, M Aseafan, et al.
• Efficacy and tolerability of cetuximab 750 mg/m2 every three weeks in metastatic colorectal cancer; Annals of Oncology 2023
• Characteristic and clinical outcome of localized gastric cancer; real-world data; Annals of Oncology 2023
• Efficacy and prognostic significance of triflurodine/tipiracil beyond oxaliplatin and irinotecan-based chemotherapy in patients with refractory metastatic colorectal cancer: An observational multicenter study: ASCO Abstract 2021 Mohamed Alghamdi, Shouki Bazarbashi, Elsamany Shereef, Mervat Mahrous, Omar Al shaer, AhmedGad, Mohamed Aseafan, Mai Abdelgelil,, Redhwan Alshabi, Hosam Alghanmi, Nasser Nasser, HussamElhariry, Abdulaziz Al Hamad, Khalid Al-Saleh, Nashwa Abdelaziz
• Patient's characteristics and outcome of small bowel adenocarcinoma in Saudi Arabia: ASCO Abstract 2021 Bader I Alshamsan, Ahmed ali Badran, Mohamed Aseafan, Amgad Shaheen, Mahmoud AbdelsatarElshenawy, Ali H Aljubran.
• Neutrophil-to-lymphocyte ratio as a prognostic factor for neoadjuvant chemotherapy for locally advanced breast cancer: ESMO Abstract & poster 2020 B. Alshamsan, M.J. Aseafan, N. Fahmy, A. badran, T. Elhassan, M.A. Elshenawy, A. Alsayed, K. Suleman, D.S. Ajarim, T.Al-Tweigeri

• Attended EMUC 2025 in Prague
• Attended Annual ESMO meeting in Berlin 2025
• Speaker & Moderator in the 15th International Gastrointestinal Cancers Conference in Antalya
• Chairman & member of scientific committee of Saudi Gynecological Oncology Congress & SGO select 2025 & 2026 Riyadh, Saudi Arabia
• Speaker at 10th & 11th annual meeting masterclass for gynecologic malignancy 2025&2026, Riyadh.
• Speaker at GU Oncology Masterclass 2025 & 2026 at Riyadh, Saudi Arabia
• Speaker at Best of SABCS 2024 & 2025 at Jeddah, Saudi Arabia.
• Speaker at 3rd MESTERO conference at Riyadh, Saudi Arabia.
• Speaker at IGCC meeting 2024 & 2025 at Jeddah, Saudi Arabia
• Speaker at Best of ASCO 2022 & 2023 & 2024 & 2025 at Dammam, Saudi Arabia
• Speaker at 3rd MESTERO conference at Riyadh, Saudi Arabia.
• Attended ESMO congress 2024 at Barcelona, Spain.
• Attended ASCO annual meeting 2024 (virtual)
• Attended SGO 2024 (virtual).
• Attended ESGO congress 2024 at Barcelona, Spain.
• Speaker at 3rd & 4th & 5th Controversies in GI/GU Oncology 2023 & 2024 & 2025 at KFSH&RC, Riyadh.
• Moderator at Best of SABCS 2023 at Riyadh, KSA
• Attended Practical Cancer Genomics for Oncologists (Online) 2023, St George's University of London
• Attended ESGO congress 2023 at Istanbul, Turkiye
• Attended ESMO congress 2023 at Madrid, Spain
• Attended ASCO annual meeting (virtual), 2023
• Speaker at 2nd Controversies in GI/GU Oncology 2023 at KFSH&RC, Riyadh.
• Moderator at 8th annual meeting masterclass for gynecologic malignancy 2023, Riyadh.
• Attended ASCO annual meeting (virtual), 2022